Median [IQR] diabetes durations in the SGLT2 inhibitor group was 5.96 [2.80–9.35] years and, similarly, 5.91 [2.80–9.61] in the controls, and mean ( ± SD) CCI scores were 0.76 ( ± 1.19) and 0.79 ( ± 1.19) in the SGLT2 inhibitor and control group, respectively. This evidence concerns the gene SLC5A2 and diabetes mellitus.